Underground Biohacking
Cognition

Cerebrolysin

Chris Hallewell, founder of Underground Biohacking

By , Founder, Underground Biohacking

Last reviewed

Prescription / research only

Cerebrolysin is a mix of peptides and amino acids made from pig brain tissue. It is given by injection in parts of Europe and Asia. Real human trials exist, and some are positive. But the Cochrane review of acute ischaemic stroke found no benefit on death. It also found more non fatal serious adverse events. Results in dementia and head injury look better, though reviewers rated that evidence weak. It is not approved in the United States.

What is Cerebrolysin?

Cerebrolysin is a liquid drug made from pig brain tissue. Makers break the tissue down using enzymes. The result is a mix of low molecular weight peptides (short chains of amino acids) and free amino acids. It belongs to a class called neurotrophic agents. Neurotrophic factors are natural signals that help brain cells survive and grow. The peptides in cerebrolysin are meant to copy some of those signals. That idea is the basis for its use after stroke, after head injury, and in dementia. Structure matters here in an unusual way. Cerebrolysin is not a single molecule. It is a biological mixture, so no one active ingredient can be named or measured. Each batch is defined by how it was made. That makes the product hard to standardise and hard to compare across trials. Doctors give it into a vein or a muscle, never by mouth. Peptides that are swallowed get broken down before they reach the blood.

What is Cerebrolysin prescribed for?

  • In people recovering from stroke, arm and hand function at 90 days beat placebo in a multicentre trial.[3]Human study
  • Pooling both CARS trials in people, early stroke rehabilitation patients did better on motor and neurological measures.[4]Human study
  • In people with vascular dementia, adding it to aspirin improved clinical outcome over 24 weeks.[5]Human study
  • A Cochrane review of six vascular dementia trials in people found better cognition and general function.[2]Human study
  • In people with mild to moderate Alzheimer's disease, pooled trials showed an overall benefit versus placebo.[6]Human study
  • In people with moderate to severe head injury, two pooled trials reported a benefit on recovery.[7]Human study
  • In rats with a closed head injury, it cut nerve fibre damage and scarring and raised new cell growth.[9]Animal or lab study only

How does Cerebrolysin work?

Cerebrolysin isn't a single molecule. It's a mixture made from pig brain protein, broken down into small peptides and free amino acids. It's given by injection. Researchers describe it as acting like your own neurotrophic factors. Those are the proteins that help nerve cells grow, survive, and form new connections. Reviews report it copies some of that activity and shifts how much of those factors your brain makes. The limits matter here. Nobody has pinned down which peptide in the mixture does what, or which receptor it acts on. The neurotrophic mechanism is proposed, not proven.

Educational reference only. Talk to a licensed clinician for any decisions on Cerebrolysin.

What are the side effects of Cerebrolysin?

EffectHow seriousWhat to watch
More non fatal serious adverse events than placebo in acute ischaemic stroke trials.[1]SeriousAny new medical event during treatment, reported to the treating doctor at once.
Dizziness or vertigo was the side effect reported most often across dementia trials.[8]Mild to moderateBalance, spinning sensations, and fall risk, especially in older people.
The overall number of people reporting any adverse event was close to placebo in stroke trials.[1]Low certaintyNone specific, but the evidence behind this was rated low quality.
Death from any cause was not raised compared with placebo in acute stroke trials.[1]No signal foundNone.
In vascular dementia trials, side effect rates did not differ from placebo, on very weak evidence.[2]UnknownGeneral tolerance, since the pooled safety data came from only two small studies.

Is Cerebrolysin legal in 2026?

Checked on 6 August 2026. Cerebrolysin is not approved by the FDA for any use in the United States. The primary source is an FDA warning letter dated 1 April 2020 to a compounding pharmacy. That letter names cerebrolysin among the bulk substances the firm used. It states that drug products compounded with those substances are not eligible for the exemptions in section 503A. The reason given is threefold. They are not the subject of a USP or NF monograph. They are not a component of an FDA approved human drug. And they do not appear on the 503A bulks list. Nothing in that position has changed. Outside the United States, cerebrolysin is licensed and prescribed in a number of countries.

Status checked against the primary source.

Educational reference only. Talk to a licensed clinician for any decisions on Cerebrolysin.

If you are considering Cerebrolysin

This page does not provide dosing, cycling, stacking, or sourcing guidance for Cerebrolysin. The protocol conversation belongs with a licensed clinician who can review your bloodwork, history, and goals.

Where to buy Cerebrolysin

Running Cerebrolysin in your next protocol cycle?

Check out our recommended sources list to find vetted vendors you can trust.

View sources

Frequently Asked Questions

Does cerebrolysin work after a stroke?
It depends which question you ask. The Cochrane review of acute ischaemic stroke found no benefit on death. It also found a likely rise in non fatal serious adverse events. A separate trial in stroke rehabilitation, called CARS, did show better arm function at 90 days. Those two findings sit side by side. Treating early to save brain tissue looks unsupported. Treating later to aid recovery looks more promising, but still needs a large confirming trial.
What did the Cochrane reviews actually find?
There are two of them. The acute ischaemic stroke review pooled seven trials and 1,773 people. It found no effect on all cause death, and a probable increase in non fatal serious adverse events. The vascular dementia review pooled six trials and 597 people. It found better cognition and general function, but graded that evidence very low quality. Its authors warned the effects, if real, may be too small to be clinically meaningful.
Is cerebrolysin safe?
The total number of people reporting any side effect looked similar to placebo. Dizziness or vertigo was the problem reported most often. The concern is narrower than that. In acute stroke trials, non fatal serious adverse events were more common with cerebrolysin. Death rates were not raised. It is made from pig brain tissue. It is given by injection or drip in a clinical setting. That is not something a person can assess alone.
Is cerebrolysin approved in the United States?
No. The FDA has not approved cerebrolysin for any use. An FDA warning letter from April 2020 names it among bulk substances a compounding pharmacy had used. The letter says products compounded with it do not qualify for the section 503A exemptions. It has no USP monograph, is not part of any FDA approved human drug, and is not on the 503A bulks list. It is licensed and used in a number of other countries.
Does it improve memory or focus in healthy people?
Nobody knows. Every trial described on this page enrolled patients with a diagnosis: stroke, vascular dementia, Alzheimer's disease, or traumatic brain injury. No published trial has tested cerebrolysin in healthy adults for memory or focus. Results measured in a damaged brain do not transfer to a healthy one. A drug that aids recovery after injury may do nothing when there is nothing to recover from. Treat any cognitive enhancement claim as untested.
What should I ask a doctor about it?
Start with the condition. Ask whether your diagnosis matches a population that has actually been studied. Ask how strong the evidence is for that group, because it ranges from moderate down to very low. Ask about the reported rise in non fatal serious adverse events after stroke. Ask what proven treatment you would be using instead of it, or alongside it. And ask what would count as it working, and by when.

References

  1. 1.Ziganshina LE, et al. (2023). Cerebrolysin for acute ischaemic stroke. The Cochrane database of systematic reviews. PMID: 37818733. DOI: 10.1002/14651858.CD007026.pub7.
  2. 2.Cui S, et al. (2019). Cerebrolysin for vascular dementia. The Cochrane database of systematic reviews. PMID: 31710397. DOI: 10.1002/14651858.CD008900.pub3.
  3. 3.Muresanu DF, et al. (2015). Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. PMID: 26564102. DOI: 10.1161/STROKEAHA.115.009416.
  4. 4.Guekht A, et al. (2017). Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. PMID: 28707130. DOI: 10.1007/s10072-017-3037-z.
  5. 5.Guekht AB, et al. (2010). Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. PMID: 20656516. DOI: 10.1016/j.jstrokecerebrovasdis.2010.01.012.
  6. 6.Gauthier S, et al. (2015). Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials. Dementia and geriatric cognitive disorders. PMID: 25832905. DOI: 10.1159/000377672.
  7. 7.Vester JC, et al. (2021). Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. PMID: 33620612. DOI: 10.1007/s10072-020-04974-6.
  8. 8.Plosker GL, Gauthier S (2009). Cerebrolysin: a review of its use in dementia. Drugs & aging. PMID: 19848437. DOI: 10.2165/11203320-000000000-00000.
  9. 9.Zhang Y, et al. (2018). Cerebrolysin Reduces Astrogliosis and Axonal Injury and Enhances Neurogenesis in Rats After Closed Head Injury. Neurorehabilitation and neural repair. PMID: 30499355. DOI: 10.1177/1545968318809916.

One more time, because it matters

This page exists to identify Cerebrolysin and explain what the research describes. Underground Biohacking does not advise on dosage, cycling, stacking, or where to source prescription compounds. If Cerebrolysin is part of your plan, that conversation belongs with a clinician who can review your labs, history, and goals. Not with a website.